Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study.

Leukemia · 2018 · PMC6087720 · PMID 29572505

Europe PMC DOI

hedged sentence

0.0621

closest p · 1.2× alpha

0.0621

boldest claim

The sentences

showed a trendP = 0.0621so close (0.05 < p ≤ 0.1)

At the final analysis, OS showed a trend in favor of ibrutinib versus temsirolimus (30.3 vs. 23.5 months; HR 0.74 [95% CI 0.54–1.02], P = 0.0621).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.